ArticleDiscover oncology2025
Proliferation-cycle gene signatures predict immune landscape and prognosis in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDespite advancements in diagnostic techniques and therapeutic strategies, the prognosis for Lung adenocarcinoma (LUAD) patients remains poor. Cell proliferation and cycle dysregulation drive cancer via uncontrolled cell growth. These genes also modulate tumor immune microenvironment (TIME), yet the precise mechanisms in LUAD remain largely unknown. METHODS AND
resultsThis study aimed to identify key proliferation-cycle genes in LUAD, characterize the TIME associated with proliferation-cycle gene signatures and assess the impact of proliferation-cycle gene signatures on immunotherapy responsiveness. We analyzed The Cancer Genome Atlas (TCGA) LUAD transcriptomic data and identified eight proliferation-cycle-related risk genes (seven up-regulated: FAP, IL2RA, ITGA2, CHORDC1, PIM2, POU3F2, CD180; one down-regulated: FKBP1B). Independent cross-validation using the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) dataset confirmed the consistent expression patterns for all eight candidate genes in LUAD tumors. A risk model based on these genes stratified patients into distinct prognostic groups, revealing: (1) Survival disparity: High-risk patients exhibited poorer overall survival (p = 6.2e−05). (2) Immunosuppressive TIME: Elevated risk scores correlated with enhanced immune infiltration (p = 2.9e−12), enriched immunosuppressive populations (Tregs), reduced cytotoxic effectors (CD8+ T cells), and up-regulated immune checkpoint molecules (PDCD1/PD-L1, CTLA4). (3) Scientific implications: Risk signatures exhibited no significant correlation with tumor mutational burden (TMB), yet uncovered novel candidate targets with therapeutic potential, meriting further mechanistic exploration.
conclusionProliferation-cycle gene signatures are robust biomarkers for LUAD risk stratification, prognosis, and immune landscape prediction. Their mechanistic integration into multi-dimensional oncological models could reveal previously unrecognized layers of antitumor immune regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.